Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Eggermont, A.M.M.
Suciu, S.
MacKie, R.
Ruka, W.
Testori, A.
Kruit, W.
Punt, C.J.A.
Delauney, M.
Sales, F.
Groenewegen, G.
Ruiter, D.J.
Jagiello, I.
Stoitchkov, K.
Keilholz, U.
Lienard, D.

January 2005

Contains fulltext : 49192.pdf (publisher's version ) (Closed access)BACKGROUND: In...

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont, A.M.M.
Suciu, S.
Santinami, M.
Testori, A.
Kruit, W.H.
Marsden, J.
Punt, C.J.A.
Sales, F.
Gore, M.
MacKie, R.
Kusic, Z.
Dummer, R.
Hauschild, A.
Musat, E.
Spatz, A.
Keilholz, U.

January 2008

Contains fulltext : 69569.pdf (publisher's version ) (Closed access)BACKGROUND: An...

Treatment of Patients With Metastatic Melanoma With

Autologous Tumor-infiltrating
Steven A. Rosenberg
John R
James C. Yang
L. Topalian
Schwartzentruber Jeffrey S
David R. Parkinson
Jan H. Einhorn
Donald E. White

October 2016

infiltrating lymphocytes (TILs) derived from patients with a variety of his-tologic types of cancer ...

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Keilholz, U.
Punt, C.J.A.
Gore, M.
Kruit, W.
Patel, P.
Lienard, D.
Thomas, J.
Proebstle, T.M.
Schmittel, A.
Schadendorf, D.
Velu, T.
Negrier, S.
Kleeberg, U.R.
Lehman, F.
Suciu, S.
Eggermont, A.M.M.

January 2005

Contains fulltext : 49220schadendorf.pdf (publisher's version ) (Closed access)BAC...

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

Keilholz, U.
Goey, S.H.
Punt, C.J.
Proebstle, T.M.
Salzmann, R.
Scheibenbogen, C.
Schadendorf, D.
Liénard, D.
Enk, A.
Dummer, R.
Hantich, B.
Geueke, A.M.
Eggermont, A.M.

January 1997

PURPOSE: The combination of interferon alfa-2a (IFN alpha) and high-dose interleukin-2 (IL-2) is act...

Combination chemotherapy together with interferon-alpha (IFN-alpha) in metastatic melanoma (MM), a multicenter phase II study

Punt, C.J.A.
Jansen, R.L.H.
Vreugdenhil, A.
Mulder, P.H.M. de

January 1995

Contains fulltext : 21726___.PDF (publisher's version ) (Open Access

Phase II Trial of Cisplatin and a-Interferon in Advanced Malignant Melanoma

A. Margolin
James H. Doroshow
Steven A. Akman
Lucille A. Leong
Robert J. Morgan
George Somlo
James Raschko
Cynthia Pereira
Lisa Yonemoto
Chul Ahn

January 1992

Purpose: To evaluate the antitumor activity of combi-nation cisplatin (CDDP) and a-interferon (a-IFN...

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study

Punt, C.J.A.
Herpen, C.M.L. van
Jansen, R.L.H.
Vreugdenhil, A.
Muller, E.W.
Mulder, P.H.M. de

January 1997

Contains fulltext : 25471.PDF (publisher's version ) (Open Access

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

A. Rosenberg
James C. Yang
Douglas J. Schwartzentruber
Patrick Hwu
Francesco M. Marincola
Suzanne L. Topalian
Jan H. Einhorn
Donald E. White
Seth M. Steinberg

January 1999

Purpose: The combination of chemotherapy with im-munotherapeutic agents such as interleukin-2 and in...

A Phase II Trial of Recombinant Interferon Alpha-2b and Cisplatin in Metastatic Melanoma

Lars Bastholt
Janne Bække
Carsten Rytter
Henning Mouridsen
Ebbe Lindegård Madsen
Kirsten Møholt
Lars Bastholt

January 2000

A phase II trial of recombinant interferon alpha-2b and cisplatin in metastatic melanom

Dose efficacy study of two schedules of high-dose bolus administration of interleukin-2 and interferon alpha in metastatic melanoma

Kruit, W.H.J.
Punt, C.J.A.
Goey, S.H.
Mulder, P.H.M. de
Gratama, J.W.
Eggermont, A.M.M.
Bolhuis, R.L.H.
Stoter, G.J.

January 1996

Contains fulltext : 23736.PDF (publisher's version ) (Open Access

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.

Keilholz, U.
Martus, P.
Punt, C.J.A.
Kruit, W.
Mooser, G.
Schadendorf, D.
Lienard, D.
Dummer, R.
Koller, W.
Voit, C.
Eggermont, A.M.M.

January 2002

Item does not contain fulltextThe aim of this study was to define prognostic factors for survival, a...

On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Bernsen, M.R.
Hakansson, L.
Gustafsson, B.
Krysander, L.
Rettrup, B.
Ruiter, D.J.
Hakansson, A.

January 2003

Item does not contain fulltextA large number of studies have indicated that specific immune reactivi...

Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma--a pilot study.

BERNENGO MG
DOVEIL GC
BERTERO M
QUAGLINO P
FIERRO MT
P. SAVOIA
APPINO A
COLONNA S

January 1996

Recently, Khayat et al. reported that high-dose recombinant interleukin-2 (rIL-2) i.v. may induce tu...

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.

Bottomley, A.
Coens, C.
Suciu, S.
Santinami, M.
Kruit, W.
Testori, A.
Marsden, J.
Punt, C.J.A.
Sales, F.
Gore, M.
MacKie, R.
Kusic, Z.
Dummer, R.
Patel, P.
Schadendorf, D.
Spatz, A.
Keilholz, U.
Eggermont, A.M.M.

January 2009

Contains fulltext : 79882schadendorf.pdf (publisher's version ) (Closed access)PUR...

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Eggermont, A.M.M.
Suciu, S.
MacKie, R.
Ruka, W.
Testori, A.
Kruit, W.
Punt, C.J.A.
Delauney, M.
Sales, F.
Groenewegen, G.
Ruiter, D.J.
Jagiello, I.
Stoitchkov, K.
Keilholz, U.
Lienard, D.

January 2005

Contains fulltext : 49192.pdf (publisher's version ) (Closed access)BACKGROUND: In...

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont, A.M.M.
Suciu, S.
Santinami, M.
Testori, A.
Kruit, W.H.
Marsden, J.
Punt, C.J.A.
Sales, F.
Gore, M.
MacKie, R.
Kusic, Z.
Dummer, R.
Hauschild, A.
Musat, E.
Spatz, A.
Keilholz, U.

January 2008

Contains fulltext : 69569.pdf (publisher's version ) (Closed access)BACKGROUND: An...

Treatment of Patients With Metastatic Melanoma With

Autologous Tumor-infiltrating
Steven A. Rosenberg
John R
James C. Yang
L. Topalian
Schwartzentruber Jeffrey S
David R. Parkinson
Jan H. Einhorn
Donald E. White

October 2016

infiltrating lymphocytes (TILs) derived from patients with a variety of his-tologic types of cancer ...

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Keilholz, U.
Punt, C.J.A.
Gore, M.
Kruit, W.
Patel, P.
Lienard, D.
Thomas, J.
Proebstle, T.M.
Schmittel, A.
Schadendorf, D.
Velu, T.
Negrier, S.
Kleeberg, U.R.
Lehman, F.
Suciu, S.
Eggermont, A.M.M.

January 2005

Contains fulltext : 49220schadendorf.pdf (publisher's version ) (Closed access)BAC...

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.

Keilholz, U.
Goey, S.H.
Punt, C.J.
Proebstle, T.M.
Salzmann, R.
Scheibenbogen, C.
Schadendorf, D.
Liénard, D.
Enk, A.
Dummer, R.
Hantich, B.
Geueke, A.M.
Eggermont, A.M.

January 1997

PURPOSE: The combination of interferon alfa-2a (IFN alpha) and high-dose interleukin-2 (IL-2) is act...

Combination chemotherapy together with interferon-alpha (IFN-alpha) in metastatic melanoma (MM), a multicenter phase II study

Punt, C.J.A.
Jansen, R.L.H.
Vreugdenhil, A.
Mulder, P.H.M. de

January 1995

Contains fulltext : 21726___.PDF (publisher's version ) (Open Access

Phase II Trial of Cisplatin and a-Interferon in Advanced Malignant Melanoma

A. Margolin
James H. Doroshow
Steven A. Akman
Lucille A. Leong
Robert J. Morgan
George Somlo
James Raschko
Cynthia Pereira
Lisa Yonemoto
Chul Ahn

January 1992

Purpose: To evaluate the antitumor activity of combi-nation cisplatin (CDDP) and a-interferon (a-IFN...

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study

Punt, C.J.A.
Herpen, C.M.L. van
Jansen, R.L.H.
Vreugdenhil, A.
Muller, E.W.
Mulder, P.H.M. de

January 1997

Contains fulltext : 25471.PDF (publisher's version ) (Open Access

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

A. Rosenberg
James C. Yang
Douglas J. Schwartzentruber
Patrick Hwu
Francesco M. Marincola
Suzanne L. Topalian
Jan H. Einhorn
Donald E. White
Seth M. Steinberg

January 1999

Purpose: The combination of chemotherapy with im-munotherapeutic agents such as interleukin-2 and in...

A Phase II Trial of Recombinant Interferon Alpha-2b and Cisplatin in Metastatic Melanoma

Lars Bastholt
Janne Bække
Carsten Rytter
Henning Mouridsen
Ebbe Lindegård Madsen
Kirsten Møholt
Lars Bastholt

January 2000

A phase II trial of recombinant interferon alpha-2b and cisplatin in metastatic melanom

Dose efficacy study of two schedules of high-dose bolus administration of interleukin-2 and interferon alpha in metastatic melanoma

Kruit, W.H.J.
Punt, C.J.A.
Goey, S.H.
Mulder, P.H.M. de
Gratama, J.W.
Eggermont, A.M.M.
Bolhuis, R.L.H.
Stoter, G.J.

January 1996

Contains fulltext : 23736.PDF (publisher's version ) (Open Access

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin.

Keilholz, U.
Martus, P.
Punt, C.J.A.
Kruit, W.
Mooser, G.
Schadendorf, D.
Lienard, D.
Dummer, R.
Koller, W.
Voit, C.
Eggermont, A.M.M.

January 2002

Item does not contain fulltextThe aim of this study was to define prognostic factors for survival, a...

On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Bernsen, M.R.
Hakansson, L.
Gustafsson, B.
Krysander, L.
Rettrup, B.
Ruiter, D.J.
Hakansson, A.

January 2003

Item does not contain fulltextA large number of studies have indicated that specific immune reactivi...

Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma--a pilot study.

BERNENGO MG
DOVEIL GC
BERTERO M
QUAGLINO P
FIERRO MT
P. SAVOIA
APPINO A
COLONNA S

January 1996

Recently, Khayat et al. reported that high-dose recombinant interleukin-2 (rIL-2) i.v. may induce tu...

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.

Bottomley, A.
Coens, C.
Suciu, S.
Santinami, M.
Kruit, W.
Testori, A.
Marsden, J.
Punt, C.J.A.
Sales, F.
Gore, M.
MacKie, R.
Kusic, Z.
Dummer, R.
Patel, P.
Schadendorf, D.
Spatz, A.
Keilholz, U.
Eggermont, A.M.M.

January 2009

Contains fulltext : 79882schadendorf.pdf (publisher's version ) (Closed access)PUR...

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

Eggermont, A.M.M.
Suciu, S.
MacKie, R.
Ruka, W.
Testori, A.
Kruit, W.
Punt, C.J.A.
Delauney, M.
Sales, F.
Groenewegen, G.
Ruiter, D.J.
Jagiello, I.
Stoitchkov, K.
Keilholz, U.
Lienard, D.

January 2005

Contains fulltext : 49192.pdf (publisher's version ) (Closed access)BACKGROUND: In...

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont, A.M.M.
Suciu, S.
Santinami, M.
Testori, A.
Kruit, W.H.
Marsden, J.
Punt, C.J.A.
Sales, F.
Gore, M.
MacKie, R.
Kusic, Z.
Dummer, R.
Hauschild, A.
Musat, E.
Spatz, A.
Keilholz, U.

January 2008

Contains fulltext : 69569.pdf (publisher's version ) (Closed access)BACKGROUND: An...

Treatment of Patients With Metastatic Melanoma With

Autologous Tumor-infiltrating
Steven A. Rosenberg
John R
James C. Yang
L. Topalian
Schwartzentruber Jeffrey S
David R. Parkinson
Jan H. Einhorn
Donald E. White

October 2016

infiltrating lymphocytes (TILs) derived from patients with a variety of his-tologic types of cancer ...

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

Abstract

Extracted data

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

Abstract

Extracted data

Related items

Related items